Apogee Therapeutics Inc to Discuss APG777 Asthma Phase 1b Interim Results Transcript
Good morning, and welcome to Apogee Therapeutics conference call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
I will now turn the call over to Noel Kurdi, Vice President of Investor Relations at Apogee. Noel, you may begin.
Thank you, operator, and thank you all for joining us today. During this call, we'll be making forward-looking statements related to our current expectations and plans for the company as well as our clinical and preclinical programs. These statements represent our views as of this date and should not be relied upon as representing our views as of any subsequent date in the future.
Looking at our agenda today, CEO, Michael Henderson will begin the call with an introduction to Apogee's latest developments and our goal of delivering a pipeline (inaudible) product with our lead program, [Zumilokibart], or APG777. Chief Medical Officer, Carl Dambkowski, will then walk us through the Phase 1b interim results of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
